BIIB Biogen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIIB

Price (delayed)

$202.95

Market cap

$29.99B

P/E Ratio

35.73

Dividend/share

N/A

EPS

$5.68

Enterprise value

$37.06B

?
Relative Growth: Rel. Growth: 17
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 38
Relative Profitability: Rel. Profitability: 52

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with ...

Highlights
The equity has grown by 7% YoY
The P/E is 78% above the 5-year quarterly average of 20.1 and 58% above the last 4 quarters average of 22.6
The company's quick ratio has shrunk by 54% QoQ and by 38% YoY
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.biogen.com
Peers: AMGN GILD PFE ABBV

Key stats

What are the main financial stats of BIIB

BIIB stock price

How has the Biogen stock price performed over time
Intraday
-2.4%
1 week
0.38%
1 month
-6.07%
1 year
58.55%
YTD
15.32%
QTD
-6.07%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$10.03B
Gross profit
$7.42B
Operating income
$1.01B
Net income
$834.6M
Gross margin
74%
Net margin
8.3%
Biogen's net margin has decreased by 46% YoY and by 40% from the previous quarter
Biogen's net income has decreased by 45% YoY and by 39% QoQ
Biogen's operating margin has decreased by 44% YoY and by 38% from the previous quarter
BIIB's operating income is down by 44% year-on-year and by 38% since the previous quarter

Price vs fundamentals

How does BIIB's price correlate with its fundamentals

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
BIIB P/E details
P/E
35.73
P/B
1.59
P/S
2.99
EV/EBIT
36.64
EV/EBITDA
19.94
EV/Sales
3.7
The P/E is 78% above the 5-year quarterly average of 20.1 and 58% above the last 4 quarters average of 22.6
The EPS has contracted by 46% YoY and by 39% from the previous quarter
BIIB's price to book (P/B) is 28% lower than its 5-year quarterly average of 2.2 but 14% higher than its last 4 quarters average of 1.4
The equity has grown by 7% YoY
The stock's price to sales (P/S) is 15% more than its last 4 quarters average of 2.6 but 3.5% less than its 5-year quarterly average of 3.1

Efficiency

How efficient is Biogen business performance
The ROIC has plunged by 54% YoY and by 39% from the previous quarter
The ROE has plunged by 50% YoY and by 40% from the previous quarter
Biogen's return on assets has decreased by 48% YoY and by 40% QoQ
The ROS has contracted by 44% YoY and by 38% from the previous quarter

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 142% more than the total liabilities
The company's quick ratio has shrunk by 54% QoQ and by 38% YoY
The current ratio has contracted by 39% from the previous quarter and by 25% YoY
Biogen's debt is 56% less than its equity
Biogen's debt has increased by 27% from the previous quarter and by 27% YoY
The debt to equity has increased by 26% from the previous quarter and by 19% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.